Anti-high Mobility Group Box-1 Antibody Therapy for Traumatic Brain Injury

DOI Web Site Web Site PubMed 15 References
  • Okuma Yu
    Department of Pharmacology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences Department of Neurological Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences Department of Neurological Surgery, Hiroshima City Hospital
  • Date Isao
    Department of Neurological Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
  • Nishibori Masahiro
    Department of Pharmacology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences

Bibliographic Information

Other Title
  • 外傷性脳傷害に対する抗HMGB-1抗体治療
  • Symposium Review 外傷性脳傷害に対する抗HMGB-1抗体治療
  • Symposium Review ガイショウセイ ノウ ショウガイ ニ タイスル コウHMGB-1 コウタイ チリョウ

Search this article

Abstract

  Traumatic brain injury (TBI) is one of the major causes of death and aftereffects in young individuals worldwide; however, efficient therapies for TBI are lacking at present. High mobility group box-1 (HMGB-1), which is recognized as a representative of danger-associated molecular patterns (DAMPs), plays an important role in triggering inflammatory responses in many types of diseases. We presented the involvement of HMGB-1 in TBI and evaluated the ability of intravenously administered neutralizing anti-HMGB-1 monoclonal antibody (mAb) to attenuate brain injury. Anti-HMGB-1 mAb may provide a novel and effective therapy for TBI by protecting against blood brain barrier disruption and reducing the inflammatory responses induced by HMGB-1.<br>

Journal

  • YAKUGAKU ZASSHI

    YAKUGAKU ZASSHI 134 (6), 701-705, 2014-06-01

    The Pharmaceutical Society of Japan

References(15)*help

See more

Keywords

Details 詳細情報について

Report a problem

Back to top